A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

NCT02997202 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

356

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: gilteritinib
DRUG: Placebo

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

[object Object]
[object Object]